Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Partner and Localizer of BRCA2"'
Autor:
Özge Şebnem Çıldır, Özge Özmen, Selim Kul, Ali Rişvanlı, Gözde Özalp, Ahmet Sabuncu, Oğuz Kul
Publikováno v:
Veterinary Medicine and Science, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract Background DNA repair mechanisms are essential for tumorigenesis and disruption of HR mechanism is an important predisposing factor of human breast cancers (BC). PALB2 is an important part of the HR. There are similarities between canine mam
Externí odkaz:
https://doaj.org/article/313b87b9b8e0462e9d3cdbd978e5a92d
Autor:
Semiramis L. Carbajal-Mamani, Merry J. Markham, Joaquín Santolaya-Forgas, Jacqueline C. Castagno, Joel Cardenas-Goicoechea
Publikováno v:
Obstetrics & Gynecology Science, Vol 63, Iss 2, Pp 205-208 (2020)
A 50-year-old non-Hispanic white Caucasian female was diagnosed with breast cancer and was subsequently found to possess the tumorigenic ataxia telangiectasia mutated (ATM) and PALB2 variants but not the BRCA1 and BRCA2 variants. She visited the gyne
Externí odkaz:
https://doaj.org/article/51c33ce9ee564eb58bb6b7046a2ebbfa
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hao Wang, Lei Wang, Keyi Jia, Yu Liu, Sha Zhao, Wei Li, Caicun Zhou, Minlin Jiang, Bin Chen, Yayi He
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 11, Iss 10, Pp 2983-2994 (2021)
Acta Pharmaceutica Sinica B, Vol 11, Iss 10, Pp 2983-2994 (2021)
Genomic instability remains an enabling feature of cancer and promotes malignant transformation. Alterations of DNA damage response (DDR) pathways allow genomic instability, generate neoantigens, upregulate the expression of programmed death ligand 1
Publikováno v:
Advanced Drug Delivery Reviews
Graphical abstract
Even given recent advances in nanomedicine development of breast cancer treatment in recent years and promising results in pre-clinical models, cancer nanomedicines often fail at the clinical trial stage. Limitations of conven
Even given recent advances in nanomedicine development of breast cancer treatment in recent years and promising results in pre-clinical models, cancer nanomedicines often fail at the clinical trial stage. Limitations of conven
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Carbajal-Mamani, Semiramis L., Markham, Merry J., Santolaya-Forgas, Joaquín, Castagno, Jacqueline C., Cardenas-Goicoechea, Joel
Publikováno v:
Obstetrics & Gynecology Science
A 50-year-old non-Hispanic white Caucasian female was diagnosed with breast cancer and was subsequently found to possess the tumorigenic ataxia telangiectasia mutated (ATM) and PALB2 variants but not the BRCA1 and BRCA2 variants. She visited the gyne
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Weixing Zhao, Platon Selemenakis, Bo Wu, Yuxin Huang, Dauren S. Alimbetov, Claudia Wiese, Elena Pires, Neelam Sharma
Publikováno v:
The Journal of Biological Chemistry
RAD51-associated protein 1 (RAD51AP1) is a key protein in the homologous recombination (HR) DNA repair pathway. Loss of RAD51AP1 leads to defective HR, genome instability, and telomere erosion. RAD51AP1 physically interacts with the RAD51 recombinase
Publikováno v:
Oncology Letters
During DNA repair, BRCA1 and BRCA2 interact with the tumor suppressor partner and localizer of BRCA2 (PALB2). PALB2 mutations are associated with an increased risk of breast and ovarian carcinoma, and upregulated PALB2 expression is associated with p